Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2.7 million subscribers, is available in all 50 states and certain international markets including the UK, Germany, and Australia. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Last trade$17.64
Day change-$0.92 (-4.96%)
Day range$17.14 – $18.66
Volume9,238,263
Market cap$4.35B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.35B
Price / earnings
—
Price / book
13.43×
Price / sales
1.69×
EV / sales
1.98×
EV / EBITDA
-75.84×
Profitability
Earnings per share
-$0.61
Return on assets
-3.91%
Return on equity
-43.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
4.21×
Current ratio
0.93×
Quick ratio
0.87×
Cash ratio
0.41×
Cash flow
Price / cash flow
16.51×
Price / free cash flow
58.44×
Free cash flow
$74.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HIMS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$753.21M
$608.1M
$617.82M
$598.98M
$544.83M
$586.01M
$481.14M
$401.56M
Cost of revenue
$272.41M
$211.32M
$173.38M
$156.92M
$128.64M
$155.32M
$111.6M
$83.67M
Gross profit
$480.8M
$396.79M
$444.44M
$442.06M
$416.2M
$430.69M
$369.54M
$317.89M
Selling, general and administrative
$427.61M
$331.67M
$314.21M
$312.83M
$285.14M
$279.85M
$269.11M
$226.9M
Research and development
$54.9M
$46.94M
$40.96M
$40.58M
$37.85M
$29.91M
$23.75M
$21.09M
Total operating expenses
$578M
$475.11M
$435.25M
$430.25M
$389.47M
$372.79M
$350.95M
$295.51M
Operating income
-$97.19M
-$78.32M
$9.19M
$11.81M
$26.72M
$57.9M
$18.6M
$22.37M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$92.63M
-$101.55M
$18.35M
$12.22M
$32.85M
$60.5M
$22.29M
$23.59M
Income taxes
-$6.34M
-$9.44M
-$2.25M
-$3.55M
-$9.65M
$11.01M
-$3.73M
-$52M
Net income
-$86.29M
-$92.12M
$20.6M
$15.77M
$42.51M
$49.49M
$26.03M
$75.59M
Net income attributable to common shareholders
-$86.29M
-$92.12M
$20.6M
$15.77M
$42.51M
$49.49M
$26.03M
$75.59M
EBITDA
-$67.72M
-$56.37M
$27.28M
$29.48M
$37.19M
$66.17M
$24.66M
$26.76M
Basic earnings per share
-$0.37
-$0.40
$0.09
$0.07
$0.19
$0.22
$0.12
$0.35
Diluted earnings per share
-$0.37
-$0.40
$0.07
$0.06
$0.17
$0.20
$0.10
$0.32
Recent news
Company coverage with links to the original publishers.
Hims & Hers Health stock plummeted following earnings results that revealed strong 49% revenue growth but concerning profitability issues. The company posted a $66.1 million operating loss compared to an $11.8 million profit a year ago, with gross margins deteriorating from 74% to 57%. The analyst recommends avoiding the stock until the company demonstrates sustainable profitable growth.
Hims & Hers stock crashed 17% after issuing weak Q4 guidance, with revenue projections falling short of analyst expectations at $875-895 million versus expected $955.1 million. The company faces margin pressure from increased sales of lower-margin weight-loss drugs and international expansion. However, the upcoming launch of its Peptides+ category at month-end could provide significant growth opportunities, making the stock potentially attractive for long-term investors despite current headwinds.
Hims & Hers has partnered with Eli Lilly to offer FDA-approved obesity treatments Zepbound and Foundayo through its digital health platform, with self-pay prices starting at $149-$299 monthly. The partnership aims to strengthen HIMS' position in the rapidly growing weight-loss market, though revenue impact depends on patient adoption and prescription volumes. The global obesity treatment market is projected to grow from $29 billion in 2026 to $60.5 billion by 2030.
Hims & Hers Health (HIMS) has seen its stock decline 32.9% over the past month, significantly underperforming the S&P 500's -2.6% decline. The company received a Zacks Rank #4 (Sell) rating due to negative earnings estimate revisions, with current quarter EPS expected to decline 71.4% year-over-year. While revenue growth remains solid at 49.8% for the current quarter, the stock is trading at a premium valuation (Grade D) and has consistently missed EPS estimates, suggesting potential underperformance in the near term.
Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.